Top Markets
#1 MowCat MowCat +48.96%
#2 Bermuda Shorts Bermuda Shorts +30.38%
#3 Velvet Velvet +25.38%
#4 Audiera Audiera +22.91%
#5 aPriori aPriori +21.24%
#6 Derive Derive +21.04%
#7 Quack AI Quack AI +19.37%
#8 Biconomy Biconomy +18.03%
#9 Perle Perle +12.23%
#10 Geodnet Geodnet +11.94%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Medigene AG Medigene AG

Medigene AG

MDG1
Rangering i aksjer #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Aksjekurs
$0.14942078
Sist synkronisert: 2025-05-15
Markedsverdi
$3.86M
Endring (1 dag)
0.10%
Endring (1 år)
0.00%
Land
DE
Handel Medigene AG (MDG1)

Kategori

Healthcare
P/S-forhold for Medigene AG (MDG1)
P/S-forhold per August 2026 TTM: 0.33
Ifølge Medigene AG sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0.33. Ved slutten av 2022 hadde selskapet et P/S-forhold på 1.58.
P/S-historikk for Medigene AG fra 2004 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 0.33 -94.44%
2023 5.86 270.74%
2022 1.58 -76.40%
2021 6.70 -37.67%
2020 10.75 15.55%
2019 9.30 -81.25%
2018 49.61 -30.09%
2017 70.97 -38.41%
2016 115.23 29.31%
2015 89.11 1,204.14%
2014 6.83 -18.93%
2013 8.43 -29.80%
2012 12.01 -23.25%
2011 15.64 -52.41%
2010 32.87 915.33%
2009 3.24 -25.83%
2008 4.36 -43.78%
2007 7.76 51.85%
2006 5.11 -35.56%
2005 7.93 -16.62%
2004 9.52 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 3,018.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 3,006.19%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 1,354.31%
BE